Gilead's loss is B-MS' gain in battle of CAR-T subsidiaries

16 December 2019

A US jury has ordered the Gilead Sciences (Nasdaq: GILD) subsidiary Kite Pharma to pay a total of $752 million to Juno Therapeutics – which has now become part of Bristol-Myers Squibb (NYSE: BMY) – and the Memorial Sloan Kettering Cancer Center (MSKCC).

The US District Court for the Central District of California found that Kite’s CAR-T therapy Yescarta (axicabtagene ciloleucel) violated a MSKCC patent that Juno had licensed.

Gilead, which acquired Kite in 2017, has been told to pay B-MS $585 million as well as royalties of 27.6% on sales of Yescarta, which has won approvals in diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma. As the roll-out of the therapy continues across the USA and Europe, its sales for the third-quarter of this year were $118 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK